Wells Fargo’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-24
Closed -$18 7842
2023
Q4
$18 Buy
24
+1
+4% +$1 ﹤0.01% 7256
2023
Q3
$26 Buy
23
+1
+5% +$1 ﹤0.01% 7123
2023
Q2
$30 Buy
22
+9
+69% +$11 ﹤0.01% 7202
2023
Q1
$14 Hold
13
﹤0.01% 7456
2022
Q4
$31 Buy
13
+4
+44% +$10 ﹤0.01% 7164
2022
Q3
$0 Hold
9
﹤0.01% 7952
2022
Q2
$0 Buy
9
+1
+13% +$5 ﹤0.01% 8047
2022
Q1
$0 Hold
8
﹤0.01% 8377
2021
Q4
$0 Hold
8
﹤0.01% 8330
2021
Q3
$0 Sell
8
-1
-11% -$16 ﹤0.01% 7968
2021
Q2
$0 Hold
9
﹤0.01% 7924
2021
Q1
$0 Buy
9
+3
+50% +$90 ﹤0.01% 7789
2020
Q4
$0 Buy
6
+5
+500% +$98 ﹤0.01% 7453
2020
Q3
$0 Buy
+1
New +$37 ﹤0.01% 7349
2020
Q2
Hold
0
7262
2020
Q1
Hold
0
7309
2019
Q4
Hold
0
7057
2019
Q3
Hold
0
7020
2019
Q2
Hold
0
6859
2019
Q1
Hold
0
6779
2018
Q4
Hold
0
6872
2018
Q3
Hold
0
6796
2018
Q2
Hold
0
6830
2018
Q1
Hold
0
6235
2017
Q4
Hold
0
6304
2017
Q3
Sell
-1
Closed -$30.7K 6190
2017
Q2
$47K Hold
1
﹤0.01% 5404
2017
Q1
$94K Hold
1
﹤0.01% 5224
2016
Q4
$114K Hold
1
﹤0.01% 5087
2016
Q3
$77K Buy
+1
New +$125K ﹤0.01% 5069
2016
Q2
Sell
-1
Closed -$118K 5236
2016
Q1
$81K Buy
+1
New +$107K ﹤0.01% 4991
2015
Q4
Hold
0
5238
2015
Q3
Hold
0
5139
2015
Q2
Hold
0
5540

Other funds holding NVIV

Wells Fargo's NVIV Position: Q1 2024 in Review

Wells Fargo sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2024, closing a stake of 24 shares — an estimated $18 sold.

Wells Fargo first reported a position in NVIV in Q1 2016 and held it in 19 quarters. The position peaked at $114K in Q4 2016. 4 funds tracked by Wall St. Rank hold NVIV as of Q1 2024.

  • Wells Fargo reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2024 after selling out during the quarter.
  • Wells Fargo sold 24 InVivo Therapeutics Holdings Corp shares in Q1 2024, an estimated $18.
  • Wells Fargo first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 19 quarters.
  • Wells Fargo's InVivo Therapeutics Holdings Corp position peaked at $114K in Q4 2016.
  • 4 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2024.

Based on Wells Fargo's 13F filing for Q1 2024, filed 10 May 2024.